^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sirolimus

    i
    Other names: AY 22989, NSC 226080, NPC-12
    Company:
    Generic mfg.
    Drug class:
    mTOR inhibitor
    Related drugs:
    1d
    Discovery and Optimization of 4-Aminopteridin-7(8H)-one Derivatives as Potent and Selective mTOR Inhibitors with Favorable Pharmacodynamic and Safety Characteristics. (PubMed, J Med Chem)
    The mechanistic target of rapamycin (mTOR) is a central regulator of cell growth and a promising cancer therapeutic target...In the HGC-27 xenograft mouse model, oral administration of T133 exhibited dose-dependent efficacy comparable to clinical-stage inhibitor PF-04691502, while exhibiting significantly reduced hepatotoxicity, nephrotoxicity, and pulmonary toxicity. Moreover, assessments of T133 on cytochrome P450, hERG, and AMES indicate a favorable safety profile. These findings suggest T133 is a promising mTOR inhibitor, warranting further investigation for cancer therapy.
    PK/PD data • Journal
    |
    EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
    |
    sirolimus • PF-04691502
    5d
    Systematic Approach for Children With Orbital Malformation With Sirolimus Use (clinicaltrials.gov)
    P3, N=30, Recruiting, Ain Shams University
    New P3 trial
    |
    sirolimus
    6d
    A retrospective real-world study on the correlation between sirolimus blood concentration and adverse reactions in transplant patients (ChiCTR2500112928)
    P4, N=221, Not yet recruiting, Shanghai General Hospital; Shanghai General Hospital
    New P4 trial
    |
    sirolimus
    6d
    A phase Ib/II clinical trial on the safety and efficacy of sirolimus (albumin-bound) combined with different ADCs in patients with advanced solid tumors (ChiCTR2500111937)
    P1, N=444, Not yet recruiting, Fudan University Shanghai Cancer Center; CSPC Zhongqi Pharmaceutical Technology Co., Ltd.
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • CD276 (CD276 Molecule) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    HER-2 negative • HER-2 expression • EGFR expression
    |
    sirolimus • trastuzumab envedotin (DP303c) • SYS6010 • sirolimus for injection (albumin-bound) (SRL-HSA)
    8d
    Radiomics-based gradient boosting model on contrast-enhanced MRI for non-invasive prediction of epidermal growth factor receptor expression and therapeutic response to EGFR-targeted antibody-drug conjugates in high-grade glioma organoid models. (PubMed, J Transl Med)
    EGF/EGFR expression is associated with immunosuppressive microenvironments and adverse outcomes in HGG. Radiomics may provide a non-invasive approach for estimating EGFR expression, although model performance requires external validation and EGFR-ADCs showed partial inhibitory activity within the tested range, though potency remains to be defined.These findings suggest a framework into radiogenomic stratification and targeted therapy in GBM.
    Journal
    |
    mTOR (Mechanistic target of rapamycin kinase) • CD4 (CD4 Molecule)
    |
    EGFR expression • EGFR positive
    |
    temozolomide • sirolimus
    10d
    Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (clinicaltrials.gov)
    P4, N=100, Recruiting, Tongji Hospital | Enrolling by invitation --> Recruiting | Trial completion date: Dec 2025 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Oct 2026
    Enrollment status • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • sirolimus • Actemra IV (tocilizumab) • leflunomide
    10d
    Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell Transplantation. (PubMed, Blood Adv)
    The success of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis has driven efforts to optimize partner therapies that balance GVHD and relapse prevention. We report phase I dose-finding results of PTCy, sirolimus (SIR), and VIC-1911, a selective oral Aurora kinase A (AURKA) inhibitor, following myeloablative allogeneic hematopoietic cell transplantation (alloHCT)...Clinical outcomes included no grade III-IV acute GVHD through day 180 (0%) and low rates of moderate/severe chronic GVHD (6%) and relapse (0%) through 1 year (5/16 received maintenance). The 1-year overall survival for this cohort was 94%.VIC-1911 at 75 mg BID, combined with PTCy and SIR, effectively suppresses AURKA activity, offering promising GVHD and relapse prevention with a favorable safety profile and promising early clinical outcomes.
    Journal
    |
    AURKA (Aurora kinase A) • CD4 (CD4 Molecule)
    |
    cyclophosphamide • sirolimus • VIC-1911
    11d
    Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies (clinicaltrials.gov)
    P2/3, N=64, Recruiting, Federal Research Institute of Pediatric Hematology, Oncology and Immunology
    New P2/3 trial
    |
    Jakafi (ruxolitinib) • sirolimus • cyclosporin A microemulsion
    11d
    Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease (clinicaltrials.gov)
    P2, N=50, Recruiting, University of Illinois at Chicago | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    cyclophosphamide • sirolimus • fludarabine IV
    14d
    Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Case Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab) • sirolimus
    16d
    Feasibility of [11C]Acetate-PET in LAM and TSC (clinicaltrials.gov)
    P1/2, N=7, Active, not recruiting, Brigham and Women's Hospital | Recruiting --> Active, not recruiting | N=16 --> 7 | Trial completion date: Dec 2023 --> Jun 2026
    Enrollment closed • Enrollment change • Trial completion date
    |
    sirolimus
    16d
    A Pilot Study on Reverse Aging (The REVERSE Study) (clinicaltrials.gov)
    P1, N=52, Active, not recruiting, The Christ Hospital
    New P1 trial
    |
    AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
    |
    sirolimus